Details for Patent: 9,902,714
✉ Email this page to a colleague
Which drugs does patent 9,902,714 protect, and when does it expire?
Patent 9,902,714 protects BALVERSA and is included in one NDA.
This patent has thirty-nine patent family members in thirty-five countries.
Summary for Patent: 9,902,714
| Title: | Quinoxaline derivatives useful as FGFR kinase modulators |
| Abstract: | The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. |
| Inventor(s): | Wim Vermeulen, Steven Anna HOSTYN, Filip Albert Celine CUYCKENS, Russell Mark JONES, Diego Fernando Domenico BROGGINI |
| Assignee: | Janssen Pharmaceutica NV , Astex Therapeutics Ltd |
| Application Number: | US15/128,345 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,902,714 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Process; |
Drugs Protected by US Patent 9,902,714
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | 9,902,714 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-002 | Apr 12, 2019 | RX | Yes | No | 9,902,714 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | 9,902,714 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,902,714
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 14161820 | Mar 26, 2014 | |
| PCT Information | |||
| PCT Filed | March 26, 2015 | PCT Application Number: | PCT/EP2015/056507 |
| PCT Publication Date: | October 01, 2015 | PCT Publication Number: | WO2015/144803 |
International Family Members for US Patent 9,902,714
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 099854 | ⤷ Start Trial | |||
| Australia | 2015238300 | ⤷ Start Trial | |||
| Brazil | 112016022060 | ⤷ Start Trial | |||
| Canada | 2943683 | ⤷ Start Trial | |||
| Chile | 2016002382 | ⤷ Start Trial | |||
| China | 106459010 | ⤷ Start Trial | |||
| Costa Rica | 20160501 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
